Fig. 3

MRD status in blood at the end of induction, and throughout G maintenance or follow up in the Benda arm (a) and in the G-Benda arm (b). Benda bendamustine, BM bone marrow, EOI end of induction, G obinutuzumab, MRD minimal residual disease, and PB peripheral blood